MedKoo Cat#: 462547 | Name: GSK2643943A HCl

Description:

WARNING: This product is for research use only, not for human or veterinary use.

GSK2643943A is a deubiquitylating enzyme (DUB) inhibitor.

Chemical Structure

GSK2643943A HCl
GSK2643943A HCl
CAS#GSK2643943A HCl

Theoretical Analysis

MedKoo Cat#: 462547

Name: GSK2643943A HCl

CAS#: GSK2643943A HCl

Chemical Formula: C17H13ClFN3

Exact Mass: 0.0000

Molecular Weight: 313.76

Elemental Analysis: C, 65.08; H, 4.18; Cl, 11.30; F, 6.06; N, 13.39

Price and Availability

Size Price Availability Quantity
Bulk Inquiry
Buy Now
Add to Cart
Synonym
GSK2643943A; GSK-2643943A; GSK 2643943A
IUPAC/Chemical Name
(E)-2-amino-6-(3-fluorostyryl)-1H-indole-3-carbonitrile hydrochloride
InChi Key
QVZKVZCZKTXMFJ-FXRZFVDSSA-N
InChi Code
InChI=1S/C17H12FN3.ClH/c18-13-3-1-2-11(8-13)4-5-12-6-7-14-15(10-19)17(20)21-16(14)9-12;/h1-9,21H,20H2;1H/b5-4+;
SMILES Code
N#CC1=C(N)NC2=C1C=CC(/C=C/C3=CC=CC(F)=C3)=C2.[H]Cl
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>3 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info

Preparing Stock Solutions

The following data is based on the product molecular weight 313.76 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
1: Harrigan JA, Jacq X, Martin NM, Jackson SP. Deubiquitylating enzymes and drug discovery: emerging opportunities. Nat Rev Drug Discov. 2018;17(1):57-78. doi:10.1038/nrd.2017.152 2: Nishi Kumari, et al. Targeting the Ubiquitin Proteasome System in Cancer. Neoplasm. 2017 Dec.